Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8.5
USERS' SCORE
Good
Based on 5 Reviews
8.6
Top Medical Research Studies
8
We dived into how adherence to acute migraine medications influences migraine severity and patient satisfaction. Over three months, participants diligently recorded their migraine experiences in daily diaries.
With 337 adults participating, the findings showed that those using migraine-specific medication (MSM), especially when pain was milder, reported the best outcomes. This included less daily disability and greater satisfaction with their medication.
Our results suggest that starting treatment with MSM may lead to a better quality of life for migraine sufferers.
With 337 adults participating, the findings showed that those using migraine-specific medication (MSM), especially when pain was milder, reported the best outcomes. This included less daily disability and greater satisfaction with their medication.
Our results suggest that starting treatment with MSM may lead to a better quality of life for migraine sufferers.
Read More
9
Erenumab reduces migraine medication use
We explored how erenumab impacts the use of acute headache medication, especially migraine-specific medications (MSM). The study analyzed data from two major clinical trials involving patients with episodic migraine (EM) and chronic migraine (CM). Participants received either erenumab or placebo over a set period, allowing us to compare medication usage accurately.
Our findings indicate that treatment with erenumab led to a significant decrease in the number of days patients used acute headache medications, particularly in those relying on MSM. This reduction was observed in both episodic and chronic migraine patients, suggesting that erenumab not only helps manage migraines but may also help mitigate the need for additional acute treatment.
Overall, these results highlight the potential benefits of erenumab in addressing not just the frequency of migraines but also reducing dependence on medications traditionally used for acute migraine relief.
Our findings indicate that treatment with erenumab led to a significant decrease in the number of days patients used acute headache medications, particularly in those relying on MSM. This reduction was observed in both episodic and chronic migraine patients, suggesting that erenumab not only helps manage migraines but may also help mitigate the need for additional acute treatment.
Overall, these results highlight the potential benefits of erenumab in addressing not just the frequency of migraines but also reducing dependence on medications traditionally used for acute migraine relief.
Read More
Most Useful Reviews
10
Migraine support
This roll-on has been a lifesaver for my migraines and headaches. I hope it's never discontinued! It provides great distraction from the pain and helps me cope remarkably well.
Read More
9.5
Effective pain relief
I love Stop Pain! It's one of my favourite products. My daughter and I find it excellent for pain relief, applying it easily for relaxation. I frequently use it for neck tension and she uses it for headaches. Although caution is necessary due to its strong menthol, I truly appreciate its effectiveness, having relied on it for over a decade.
Read More
9.5
Reliable pain relief
I swear by this product! I use it whenever I have a headache or muscle ache, and I can’t imagine going back to anything else.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8.5
- All Researches
9
Erenumab reduces migraine medication use
We explored how erenumab impacts the use of acute headache medication, especially migraine-specific medications (MSM). The study analyzed data from two major clinical trials involving patients with episodic migraine (EM) and chronic migraine (CM). Participants received either erenumab or placebo over a set period, allowing us to compare medication usage accurately.
Our findings indicate that treatment with erenumab led to a significant decrease in the number of days patients used acute headache medications, particularly in those relying on MSM. This reduction was observed in both episodic and chronic migraine patients, suggesting that erenumab not only helps manage migraines but may also help mitigate the need for additional acute treatment.
Overall, these results highlight the potential benefits of erenumab in addressing not just the frequency of migraines but also reducing dependence on medications traditionally used for acute migraine relief.
Our findings indicate that treatment with erenumab led to a significant decrease in the number of days patients used acute headache medications, particularly in those relying on MSM. This reduction was observed in both episodic and chronic migraine patients, suggesting that erenumab not only helps manage migraines but may also help mitigate the need for additional acute treatment.
Overall, these results highlight the potential benefits of erenumab in addressing not just the frequency of migraines but also reducing dependence on medications traditionally used for acute migraine relief.
Read More
8
We dived into how adherence to acute migraine medications influences migraine severity and patient satisfaction. Over three months, participants diligently recorded their migraine experiences in daily diaries.
With 337 adults participating, the findings showed that those using migraine-specific medication (MSM), especially when pain was milder, reported the best outcomes. This included less daily disability and greater satisfaction with their medication.
Our results suggest that starting treatment with MSM may lead to a better quality of life for migraine sufferers.
With 337 adults participating, the findings showed that those using migraine-specific medication (MSM), especially when pain was milder, reported the best outcomes. This included less daily disability and greater satisfaction with their medication.
Our results suggest that starting treatment with MSM may lead to a better quality of life for migraine sufferers.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
10
Migraine support
This roll-on has been a lifesaver for my migraines and headaches. I hope it's never discontinued! It provides great distraction from the pain and helps me cope remarkably well.
Read More
9.5
Effective pain relief
I love Stop Pain! It's one of my favourite products. My daughter and I find it excellent for pain relief, applying it easily for relaxation. I frequently use it for neck tension and she uses it for headaches. Although caution is necessary due to its strong menthol, I truly appreciate its effectiveness, having relied on it for over a decade.
Read More
9.5
Reliable pain relief
I swear by this product! I use it whenever I have a headache or muscle ache, and I can’t imagine going back to anything else.
Read More
8
Travel-friendly pain relief
I buy Stopain for temporary pain relief. It effectively helps with headaches as well. I prefer the roll-on to avoid sprays that can accidentally irritate eyes. I cut the roller off to refill smaller bottles for easy carrying. The 3 oz bottle is TSA-friendly, making it a convenient option for travel. I appreciate the value it provides!
Read More
8.8
Numbs migraine pain
This is the only topical product that assists with migraine pain! While it may not eliminate migraines, it helps numb the agonising areas and makes the discomfort more bearable. Just take care not to apply it near the eyes and wash it off after use to avoid acne.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Tepper SJ, Ashina M, Reuter U, Hallström Y, Broessner G, et al. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. J Headache Pain. 2021;22:81. doi:10.1186/s10194-021-01292-w
- Seng EK, Robbins MS, Nicholson RA. Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study. Cephalalgia. 2017;37:955. doi:10.1177/0333102416663459
